Literature DB >> 28435152

Systemic lupus erythematosus: Withdrawing standard of care therapies in SLE trials?

Chi Chiu Mok1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28435152     DOI： 10.1038/nrrheum.2017.59

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  9 in total

1.  Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Authors:  J T Merrill; R F van Vollenhoven; J P Buyon; R A Furie; W Stohl; M Morgan-Cox; C Dickson; P W Anderson; C Lee; P-Y Berclaz; T Dörner
Journal:  Ann Rheum Dis       Date:  2015-08-20       Impact factor: 19.103

2.  Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

Authors:  Brad H Rovin; Richard Furie; Kevin Latinis; R John Looney; Fernando C Fervenza; Jorge Sanchez-Guerrero; Romeo Maciuca; David Zhang; Jay P Garg; Paul Brunetta; Gerald Appel
Journal:  Arthritis Rheum       Date:  2012-01-09

3.  The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials.

Authors:  Joan T Merrill; Fred Immermann; Maryann Whitley; Tianhui Zhou; Andrew Hill; Margot O'Toole; Padmalatha Reddy; Marek Honczarenko; Aikaterini Thanou; Joe Rawdon; Joel M Guthridge; Judith A James; Sudhakar Sridharan
Journal:  Arthritis Rheumatol       Date:  2017-06       Impact factor: 10.995

4.  B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.

Authors:  G Cambridge; D A Isenberg; J C W Edwards; M J Leandro; T-S Migone; M Teodorescu; W Stohl
Journal:  Ann Rheum Dis       Date:  2007-10-25       Impact factor: 19.103

5.  Treat-to-target in systemic lupus erythematosus: are we there yet?

Authors:  Chi Chiu Mok
Journal:  Expert Rev Clin Pharmacol       Date:  2016-02-19       Impact factor: 5.045

6.  Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.

Authors:  Ronald F van Vollenhoven; Michelle A Petri; Ricard Cervera; David A Roth; Beulah N Ji; Christi S Kleoudis; Z John Zhong; William Freimuth
Journal:  Ann Rheum Dis       Date:  2012-02-15       Impact factor: 19.103

7.  Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.

Authors:  Richard Furie; Munther Khamashta; Joan T Merrill; Victoria P Werth; Kenneth Kalunian; Philip Brohawn; Gabor G Illei; Jorn Drappa; Liangwei Wang; Stephen Yoo
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

8.  Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL.

Authors:  Caroline Gordon; David Wofsy; Stephen Wax; Yong Li; Claudia Pena Rossi; David Isenberg
Journal:  Arthritis Rheumatol       Date:  2016-12-02       Impact factor: 10.995

9.  Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.

Authors:  Munther Khamashta; Joan T Merrill; Victoria P Werth; Richard Furie; Kenneth Kalunian; Gabor G Illei; Jorn Drappa; Liangwei Wang; Warren Greth
Journal:  Ann Rheum Dis       Date:  2016-03-23       Impact factor: 19.103
  9 in total
  2 in total

1.  Epidemiology of the Epstein-Barr Virus in Autoimmune Inflammatory Rheumatic Diseases in Northern Brazil.

Authors:  Samires Avelino de Souza França; Julimar Benedita Gomes de Oliveira Viana; Hilda Carla Azevedo Góes; Ricardo Roberto de Souza Fonseca; Rogério Valois Laurentino; Igor Brasil Costa; Aldemir Branco Oliveira-Filho; Luiz Fernando Almeida Machado
Journal:  Viruses       Date:  2022-03-27       Impact factor: 5.818

2.  SLE: reconciling heterogeneity.

Authors:  Michael D Lockshin; Medha Barbhaiya; Peter Izmirly; Jill P Buyon; Mary K Crow
Journal:  Lupus Sci Med       Date:  2019-02-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.